Ob/Gyn & Women’s Health Institute Outcomes
Gynecologic Oncology
Gynecologic Oncology
Unless otherwise specified, outcomes reported here reflect care by our gynecologic oncology staff practicing in Cleveland Clinic facilities in Ohio.
The advent of robotic assisted laparoscopy has prompted an increase in minimally invasive procedures in the gynecologic subspecialties. Cleveland Clinic gynecologic oncology surgeons strive to provide the best care for patients while using minimally invasive procedures when possible.
Surgical Case Approach for Both Complex Benign and Malignant Cases
2019 – 2022
New Surgical Patients to Gynecologic Oncology
2019 - 2022
Surgical Approach for Endometrial Cancer
2019 - 2022
Surgical Cases Utilizing Sentinel Technology for Endometrial Cancer
2019- 2022
Optimally Debulked Primary and Secondary Cytoreduction for Ovarian Cancer
2018 – 2022
N1 is the total of primary cytoreduction cases
N2 is the total of secondary cytoreduction cases
HIPEC Cases for Ovarian Cancer
2018 - 2022
Hyperthermic Intra Peritoneal Chemotherapy (HIPEC) is a technique whereby chemotherapy is administered into the abdominal cavity at the time of surgery to remove ovarian cancer. The addition of HIPEC therapy to select women with ovarian cancer has been shown to improve both progression free and overall survival from their disease. The Cleveland Clinic has one of the largest HIPEC programs for women with ovarian cancer in the country and is one of only a few programs that has a translation research program dedicated to investigating this promising new technique in Gynecologic malignancies.
Outpatient Surgery With 30 Day Admission Rate
2019 – 2022
* Readmission rates were significantly higher in 2021 due to Covid and patients delaying care thus creating more dire circumstances in their healthcare.
Inpatient Surgery With 30 Day Readmission Rate
2019 - 2022
Observed to Expected Thirty-Day Mortality Rate Following Inpatient Gynecologic Oncology Surgeryᵃ
2019 – 2022
ᵃThese data are prepared using the Vizient Clinical Database. Data from the Vizient Clinical Data Base/Resource Manager™ used by permission of Vizient. All rights reserved.
N is the total number of surgical cases for gynecologic malignancy identified by MS-DRGs 734, 735, 736, 737, 738, 739, 740, 741, 754, 755, and 756.
Number of Patients Enrolled in Clinical Trials
2018-2022
N is the total number of patients enrolled in treatment trials.
During the years 2018 through 2022 there were 181 patients enrolled to 27 open gynecologic treatment trials.
Use of Brachytherapy in Patients Treated With Primary Radiation With Curative Intent in any Stage of Cervical Cancerᵃ (N = 205)
2011-2021
ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.
Cleveland Clinic's performance was 91.7% (188 of 205 patients) from 2011-2021 for the use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer.
Chemotherapy Administered to Cervical Cancer Patients who Received Radiation for Stages IB2-IV Cancer or With Positive Pelvic Nodes, Positive Surgical Margin, and/or Positive Parametriumᵃ (N = 238)
2011-2021
ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.
Cleveland Clinic's performance was 94.5% (225 of 238 patients) from 2011-2021 for chemotherapy administered to cervical cancer patients who received radiation for stages IB2-IV cancer or with positive pelvic nodes, positive surgical margin, and/or positive parametrium.
Radiation Therapy Completed Within 60 Days of Initiation of Radiation Among Women Diagnosed With any Stage of Cervical Cancerᵃ (N = 311)
2011-2021
ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.
Cleveland Clinic's performance was 90.0% (280 of 311) patients; 95% CI, 86%-93%) from 2011-2021 for radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer.
Chemotherapy and/or Radiation Administered to Patients With Stage IIIC or IV Endometrial Cancerᵃ (N = 286)
2011-2021
ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.
Cleveland Clinic's performance was 92.7% (265 of 286 patients) from 2011-2021 for chemotherapy and/or radiation administered to patients with stage IIIC or IV endometrial cancer.
Laparoscopic or Robotic Surgery Performed for all Endometrial Cancer for all Stages Except Stage IVᵃ⁻ᵇ (N = 2395)
2011-2021
ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.
ᵇExcludes sarcoma and lymphoma
Cleveland Clinic's performance was 76.6% (1912 of 2395 patients; 95% CI) from 2011-2021 for laparoscopic or robotic surgery performed for endometrial cancer stages I-IIIC.
